

## Potential of typhoid conjugate vaccines in Malaysia

Typhoid, a serious enteric fever spread through contaminated food and water, is a substantial public health issue that disproportionately impacts children and marginalized populations in Asia and sub-Saharan Africa. The Global Burden of Disease (GBD) study estimates that, in 2021, there were more than 7 million typhoid cases and more than 93,000 typhoid deaths worldwide.<sup>1</sup> Additionally, strains of drug-resistant typhoid are spreading, causing global concern.<sup>2</sup>

### TYPHOID CONJUGATE VACCINES

Typhoid vaccination can reduce the need for antibiotics, slow expansion of drug-resistant strains, and save lives. Typhoid conjugate vaccines (TCVs) are licensed, prequalified by the World Health Organization (WHO), and have advantages over earlier typhoid vaccines. TCVs provide strong protection for at least 4 years, require only one dose, and are safe and effective for children older than 6 months of age.

Three large Phase 3 efficacy studies conducted in Bangladesh, Malawi, and Nepal showed that TCV prevented 79-85 percent of typhoid cases in children 9 months to 16 years of age. These results demonstrate that TCV is protective across diverse settings in Africa and Asia.

### WHO RECOMMENDATION

In March 2018, WHO recommended TCVs as the preferred typhoid vaccine because of its improved performance and suitability for younger children. WHO recommends the introduction of TCV be prioritized in countries with the highest burden of typhoid disease or a high burden of drug-resistant typhoid. WHO encourages routine administration to be accompanied by catch-up vaccination campaigns for children up to 15 years of age, where feasible and supported by data. Several countries have already introduced TCV into their routine immunization programs including Burkina Faso, Kenya, Liberia, Malawi, Nepal, Pakistan, Samoa, and Zimbabwe. More than 90 million children have been vaccinated with TCV.



A child smiles after receiving TCV in Nepal.  
PATH/Rocky Prajapati

### AN OPPORTUNITY FOR MALAYSIA

TCVs could benefit Malaysia, where typhoid inflicts a significant public health burden. The latest GBD analysis estimates that, in 2021, the Malaysia had:

- **31,793 typhoid cases or 100 cases per 100,000 population**, 50 percent of which were among children younger than 15 years of age; and
- **225 typhoid deaths**, 49 percent of which were among children younger than 15 years of age.<sup>1</sup>

Typhoid likely also imposes an economic burden in Malaysia. While costs of illness have not yet been evaluated for Malaysia, analyses from several other settings in Asia have found that families often bear a significant cost, especially for cases in young children.<sup>3</sup> Existing data demonstrate that vaccination with TCV in a variety of strategies and settings is cost-effective. WHO recommends cost-effectiveness analyses be part of the country decision-making and planning process to initiate programmatic use of typhoid vaccines.<sup>4</sup>

### References

1. GBD Results Tool. Available at: <http://ghdx.healthdata.org/gbd-results-tool>.
2. Wong VK, Baker S, Pickard DJ, et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of *Salmonella* Typhi identifies inter- and intracontinental transmission events. *Nature Genetics*. 2015;47:632-639.
3. Poulos C, Riewpaiboon A, Stewart JF, et al. Cost of illness due to typhoid fever in five Asian countries. *Tropical Medicine & Intl Health*. 2011;16(3): 314-323.
4. WHO. Typhoid vaccines: WHO Position paper – March 2018. *Weekly Epidemiological Record*. 2018;13(93):153-172.

Learn more and join the effort at [www.takeontyphoid.org](http://www.takeontyphoid.org).

**#TakeOnTyphoid**